Ultimovacs (OSE: ULTI)

Last close As at 24/06/2024

NOK7.55

0.06 (0.80%)

Market capitalisation

260m

Edison Investment Research is terminating coverage on Ultimovacs (ULTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Flash note

Ultimovacs — Steadfast commitment to UV1 progression

Healthcare | Flash note

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Healthcare | edison tv

Ultimovacs – executive interview

Ultimovacs_resized

Sector

Healthcare

Balance Sheet

Forecast net debt (NOKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.9 (93.9) (93.6)
Relative 5.1 (94.4) (94.3)
52 week high/low NOK160.4/NOK6.3

Financials

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures, including activity level adjustments, reprioritisation of operations and a 40% workforce reduction, to support runway extension to Q425 (the company estimates its cash burn will be NOK15m/quarter).

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (fd) (öre) P/E (x) P/CF (x)
2022A 0.0 (181.0) (167.8) (489.9) N/A N/A
2023A 0.0 (213.0) (189.2) (550.1) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free